Pharmacokinetics of isepamicin during continuous venovenous hemodiafiltration

被引:2
作者
Breilh, D
Allaouchiche, B
Jaumain, H
Boulétreau, P
Chassard, D
Malbec, I
Ducint, D
Saux, MC
机构
[1] Hop Hotel Dieu, Intens Care Unit, Dept Intens Care, F-69288 Lyon, France
[2] Univ Bordeaux 2, Haut Leveque Hosp, Clin Pharmacokinet Lab, F-33076 Bordeaux, France
[3] Hop Edouard Herriot, Dept Intens Care, Lyon, France
关键词
D O I
10.1128/AAC.43.10.2409
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The objective of this study was to analyze the pharmacokinetics of isepamicin during continuous venovenous hemodiafiltration. Six patients received 15 mg of isepamicin per kg of body weight. The mean isepamicin concentration peak in serum was 62.88 +/- 18.20 mg/liter 0.5 h after the infusion. The elimination half-life was 7.91 +/- 0.83 h, The mean total body clearance was 1.75 +/- 0.28 liters/h, and dialysate outlet (DO) clearance was 2.76 +/- 0.59 liters/h. The mean volume of distribution was 19.83 +/- 2.95 liters. The elimination half-life, DO clearance, and volume of distribution were almost constant. In this group of patients, the initial dosage of 15 mg/kg appeared to be adequate, but the dosage interval should be determined by monitoring residual isepamicin concentrations in plasma.
引用
收藏
页码:2409 / 2411
页数:3
相关论文
共 16 条
[1]  
BARR WH, 1995, J CHEMOTHERAPY, V7, P53
[2]   CLINICAL PHARMACOKINETICS DURING CONTINUOUS HEMOFILTRATION [J].
BRESSOLLE, F ;
KINOWSKI, JM ;
DELACOUSSAYE, JE ;
WYNN, N ;
ELEDJAM, JJ ;
GALTIER, M .
CLINICAL PHARMACOKINETICS, 1994, 26 (06) :457-471
[3]   ANTIMICROBIAL PRESCRIBING IN PATIENTS ON HEMOFILTRATION [J].
COTTERILL, S .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1995, 36 (05) :773-780
[4]   OPTIMAL SAMPLING TIMES FOR PHARMACOKINETIC EXPERIMENTS [J].
DARGENIO, DZ .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1981, 9 (06) :739-756
[5]  
Davies JG, 1995, BRIT J HOSP MED, V54, P524
[6]  
GERONEMUS RP, 1991, CONTRIB NEPHROL, V93, P29
[7]  
GOLPER TA, 1993, DIALYSIS TRANSPLANT, V22, P185
[8]   ISEPAMICIN DISPOSITION IN SUBJECTS WITH VARIOUS DEGREES OF RENAL-FUNCTION [J].
HALSTENSON, CE ;
KELLOWAY, JS ;
AFFRIME, MB ;
LIN, CC ;
TEAL, MA ;
SHAPIRO, BE ;
AWNI, WM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (11) :2382-2387
[9]  
JONES RN, 1995, J CHEMOTHERAPY, V7, P7
[10]  
Mentre F, 1995, J Biopharm Stat, V5, P141, DOI 10.1080/10543409508835104